Colin Hislop
As SVP Clinical Development, Dr. Colin Hislop leads Juvena’s clinical-stage drug candidates. His 36-years drug development and life science experience spans roles across multiple therapeutic areas at companies including Lilly (formerly Eli Lilly & Company), Proctor & Gamble Pharmaceuticals, CV Therapeutics, Peninsula Therapeutics, Versartis Inc., Anthera Pharmaceuticals and Eiger BioTherapeutics. His expertise encompasses early and late-stage clinical development of both small and large molecules, as well as the successful prosecution of multiple drug approvals.
Just prior to Juvena, Colin helped lead the successful prosecution of an NDA (2020) and MAA (2022) for lonafarnib to treat an ultra-rare genetic disease called Hutchinson-Guilford Progeria Syndrome. Previously Colin has held senior management positions as SVP Clinical Development and Operations for Eiger BioTherapuetics, Chief Medical Officer at Versartis Inc; SVP and Chief Medical Officer at Anthera Pharmaceuticals where he served on the leadership team to take the Company public.
Colin obtained an undergraduate degree in Medical Biochemistry from the University of Surrey and his medical degree from the Middlesex Hospital Medical School, University of London.
